Form 4: Verona Pharma CEO Reports Significant RSU Grant and Share Transactions Following Q2 Performance Achievement

Verona Pharma plc's President and CEO, David Zaccardelli, reported the vesting of previously granted Restricted Share Units, a new performance-based RSU award, and a subsequent share disposition for tax obligations.

Summary

• On July 7, 2025, David Zaccardelli, President and CEO of Verona Pharma plc, acquired 229,512 Ordinary Shares resulting from the vesting of an equal number of Restricted Share Units (RSUs).
• Concurrently on July 7, 2025, Mr. Zaccardelli was granted 675,048 new performance-based Restricted Share Units (RSUs).
• These new RSUs were earned following the Board of Directors' determination that certain performance metrics related to Q2 2025 had been achieved.
• 34% of the newly granted RSUs vested immediately on the determination date, with the remaining portion set to vest in equal quarterly installments over a two-year period on November 1, February 1, May 1, and August 1, contingent on continued service.
• On July 8, 2025, Mr. Zaccardelli disposed of 90,320 Ordinary Shares at a price of $11.4413 per share to satisfy tax withholding obligations related to the RSU vesting.
• The reported price of $11.4413 per Ordinary Share was derived from the Issuer's American Depositary Share (ADS) closing price of $91.5304 on the Nasdaq Stock Market LLC on July 3, 2025, divided by eight, as each ADS represents eight Ordinary Shares.
• Following these transactions, Mr. Zaccardelli's beneficial ownership stands at 13,329,360 Ordinary Shares, which includes 2,450,000 Ordinary Shares underlying various Restricted Share Units and 10,879,360 Ordinary Shares underlying 1,359,920 American Depositary Shares (ADSs).

Sentiment

Score: 7

Explanation: The sentiment is positive due to the achievement of performance metrics leading to a significant RSU grant, indicating strong company performance in Q2 2025, and the CEO's continued substantial beneficial ownership. The share disposition for tax is a neutral, routine event.

Positives

• The achievement of Q2 2025 performance metrics by Verona Pharma plc's management, leading to the earning and grant of 675,048 performance-based Restricted Share Units to the CEO.
• The CEO's continued significant beneficial ownership of 13,329,360 Ordinary Shares, which aligns his interests with those of the company's shareholders.

Negatives

• The disposition of 90,320 Ordinary Shares for tax withholding purposes, which, while a routine event for RSU vesting, represents a reduction in the CEO's direct shareholding.

Future Outlook

The remaining portion of the newly granted performance-based Restricted Share Units will vest in equal quarterly installments over a two-year period on November 1, February 1, May 1, and August 1, subject to the CEO's continued service to the Issuer.

Industry Context

This Form 4 filing is a standard disclosure of insider transactions, reflecting routine compensation events such as RSU grants and vesting, which are common practices in publicly traded companies to align management incentives with shareholder value. The disposition of shares for tax withholding is also a typical consequence of equity compensation vesting.

Stakeholder Impact

• Shareholders: Provides transparency into executive compensation and insider holdings, demonstrating alignment of management interests with shareholder value through equity awards.
• Employees: Reflects the company's compensation structure for executives, which may influence broader employee incentive programs.

Next Steps

• Continued quarterly vesting of the remaining performance-based Restricted Share Units on November 1, February 1, May 1, and August 1 over the next two years, subject to continued service.

Key Dates

Keywords

Verona Pharma, VRNA, Form 4, Insider Transaction, CEO, Restricted Share Units, RSUs, Share Vesting, Stock Compensation, Performance Metrics, Tax Withholding, Beneficial Ownership